167 related articles for article (PubMed ID: 22049974)
1. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
6. Platelet count less than SHARP: what does a case series reveal?
Saif MW
Expert Opin Drug Saf; 2010 Jan; 9(1):1-8. PubMed ID: 20001607
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
8. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T; Weinmann A; Schadmand-Fischer S; Spies PR; Niederle IM; Schuchmann M; Galle PR; Wörns MA
Onkologie; 2011; 34(10):538-42. PubMed ID: 21985853
[TBL] [Abstract][Full Text] [Related]
9. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Chiu J; Tang YF; Yao TJ; Wong A; Wong H; Leung R; Chan P; Cheung TT; Chan AC; Pang R; Fan ST; Poon R; Yau T
Cancer; 2012 Nov; 118(21):5293-301. PubMed ID: 22517493
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
12. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Peck-Radosavljevic M; Greten TF; Lammer J; Rosmorduc O; Sangro B; Santoro A; Bolondi L
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
14. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
17. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
19. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
20. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
